Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 6 de 6
Filtrar
Mais filtros







Base de dados
Intervalo de ano de publicação
1.
J. appl. oral sci ; 28: e20190382, 2020. tab, graf
Artigo em Inglês | LILACS, BBO | ID: biblio-1056584

RESUMO

Abstract Objective This study aimed to investigate the effects of Maras powder (a type of smokeless tobacco obtained from Nicotiana rustica Linn and mixed with the ashes of wood, especially from oak, walnut or grapevine) on the microRNA (miRNA) deregulation of oral mucosa, and it compares these effects with those of smoking. Methodology Oral mucosal samples were collected from 74 patients, consisting of 16 nonusers, 26 smokers, and 32 Maras powder users. Genes associated with oral cancer were selected and 90 microRNAs targeting these genes were identified. MicroRNA were isolated and purified using the microRNA isolation kit. MicroRNA were expressed using Fluidigm RT-PCR. Results A positive correlation between the duration of Maras powder use with miR-31 expression levels, and a negative correlation between the Maras powder chewing time and miR-372 expression levels was found. In addition, there is a negative correlation between the amount of Maras powder consumed and expression levels of miR-375, miR-378a, miR-145, and miR-10b; moreover, another negative correlation is observed between the number of cigarettes consumed and the expression levels of miR-23a, miR-23b, miR-203a, miR-200b, and miR-375. However, miR-200b and miR-92a levels were downregulated significantly more in Maras powder users when compared with smokers and nonusers (p<0.05). Conclusion The results show both chewing Maras powder and smoking have an effect on deregulation of miR-200b and miR-92a expressions. This leads to the belief that assessing the expression of these two miRNAs is a promising noninvasive method of analysis, especially in mutagen exposures. Finally, large-scale and high-throughput studies may help to identify an extensive miRNA expression profile associated with tobacco use and improve the understanding of oral malignancies.


Assuntos
Humanos , Masculino , Feminino , Adolescente , Adulto , Pessoa de Meia-Idade , Idoso , Tabaco sem Fumaça/efeitos adversos , MicroRNAs/efeitos dos fármacos , Mucosa Bucal/efeitos dos fármacos , Pós , Fatores de Tempo , Neoplasias Bucais/genética , Regulação para Baixo , Expressão Gênica , Estudos Transversais , Fatores de Risco , Análise de Variância , MicroRNAs/análise , Reação em Cadeia da Polimerase em Tempo Real
2.
Acta cir. bras ; 34(2): e201900204, 2019. tab, graf
Artigo em Inglês | LILACS | ID: biblio-989051

RESUMO

Abstract Purpose: To investigate the protective effects of salvianolic acid A (SAA) on renal damage in rats with chronic renal failure (CRF). Methods: The five-sixth nephrectomy model of CRF was successfully established in group CRF (10 rats) and group CRF+SAA (10 rats). Ten rats were selected as sham-operated group (group S), in which only the capsules of both kidneys were removed. The rats in group CRF+SAA were intragastrically administrated with 10 mg/kg SAA for 8 weeks. The blood urine nitrogen (BUN), urine creatinine (Ucr), creatinine clearance rate (Ccr), and serum uperoxide dismutase (SOD) and malondialdehyde (MDA) were tested. The expressions of transforming growth factor-β1 (TGF-β1), bone morphogenetic protein 7 (BMP-7) and Smad6 protein in renal tissue were determined. Results: After treatment, compared with group CRF, in group CRF+SAA the BUN, Scr, serum MDA and kidney/body weight ratio were decreased, the Ccr and serum SOD were increased, the TGF-β1 protein expression level in renal tissue was decreased, and the BMP-7 and Smad6 protein levels were increased (all P < 0.05). Conclusion: SAA can alleviate the renal damage in CRF rats through anti-oxidant stress, down-regulation of TGF-β1 signaling pathway and up-regulation of BMP-7/Smad6 signaling pathway.


Assuntos
Animais , Masculino , Ratos , Ácidos Cafeicos/uso terapêutico , Proteína Smad6/metabolismo , Fator de Crescimento Transformador beta1/metabolismo , Proteína Morfogenética Óssea 7/metabolismo , Falência Renal Crônica/tratamento farmacológico , Lactatos/uso terapêutico , Regulação para Baixo , Regulação para Cima , Ratos Sprague-Dawley , Modelos Animais de Doenças , Falência Renal Crônica/induzido quimicamente , Falência Renal Crônica/metabolismo , Testes de Função Renal , Nefrectomia
3.
Braz. j. med. biol. res ; 50(12): e6211, 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-888961

RESUMO

Recent evidence suggests that cell-derived circulating miRNAs may serve as biomarkers of cardiovascular diseases. However, a few studies have investigated the potential of circulating miRNAs as biomarkers for left ventricular hypertrophy (LVH). In this study, we aimed to characterize the miRNA profiles that could distinguish hypertensive patients with LHV, hypertensive patients without LVH and control subjects, and identify potential miRNAs as biomarkers of LVH. LVH was defined by left ventricular mass indexed to body surface area >125 g/m2 in men and >110 g/m2 in women and patients were classified as hypertensive when presenting a systolic blood pressure of 140 mmHg or more, or a diastolic blood pressure of 90 mmHg or more. We employed miRNA PCR array to screen serum miRNAs profiles of patients with LVH, essential hypertension and healthy subjects. We identified 75 differentially expressed miRNAs, including 49 upregulated miRNAs and 26 downregulated miRNAs between LVH and control patients. We chose 2 miRNAs with significant differences for further testing in 59 patients. RT-PCR analysis of serum samples confirmed that miR-7-5p and miR-26b-5p were upregulated in the serum of LVH hypertensive patients compared with healthy subjects. Our findings suggest that these miRNAs may play a role in the pathogenesis of hypertensive LVH and may represent novel biomarkers for this disease.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Idoso , Hipertensão/sangue , Hipertrofia Ventricular Esquerda/sangue , MicroRNAs/sangue , Análise de Variância , Biomarcadores/sangue , Estudos de Casos e Controles , Regulação para Baixo , Perfilação da Expressão Gênica/métodos , Hipertensão/genética , Hipertrofia Ventricular Esquerda/genética , Valor Preditivo dos Testes , Reação em Cadeia da Polimerase em Tempo Real , Padrões de Referência , Valores de Referência , Fatores de Risco , Regulação para Cima
4.
Braz. j. med. biol. res ; 50(6): e6050, 2017. tab, graf
Artigo em Inglês | LILACS | ID: biblio-839310

RESUMO

We aimed to investigate the potential role and mechanism of microRNA-30c (miR-30c) in the pathological development of chronic hepatitis B (CHB). The serum levels of miR-30c in hepatitis B virus (HBV) carrier Xinjiang Uygur patients with inactive, low-replicative, high-replicative and HBe antigen-positive CHB were investigated. HepG2 cells were co-transfected with pHBV1.3 and miR-30c mimic or inhibitor or scramble RNA. The effects of miR-30c dysregulation on HBV replication and gene expression, cell proliferation and cell cycle were then investigated. miR-30c was down-regulated in Xinjiang Uygur patients with CHB compared to healthy controls and its expression level discriminated HBV carrier patients with inactive, low-replicative, high-replicative and HBe antigen-positive risk for disease progression. Overexpression of miR-30c significantly inhibited HBV replication and the expressions of HBV pgRNA, capsid-associated virus DNA and Hbx in hepatoma cells. Moreover, overexpression of miR-30c significantly inhibited cell proliferation and delayed G1/S phase transition in hepatoma cells. Opposite effects were obtained after suppression of miR-30c. Our results indicate that miR-30c was down-regulated in Xinjiang Uygur patients with CHB, and miR-30c levels could serve as a marker for risk stratification of HBV infection. Down-regulation of miR-30c may result in the progression of CHB via promoting HBV replication and cell proliferation.


Assuntos
Humanos , Masculino , Feminino , Adulto , Pessoa de Meia-Idade , Progressão da Doença , Vírus da Hepatite B/genética , Hepatite B Crônica/sangue , MicroRNAs/sangue , Carcinoma Hepatocelular/genética , Carcinoma Hepatocelular/patologia , Proliferação de Células/genética , China , Regulação para Baixo , Regulação Viral da Expressão Gênica , Hepatite B Crônica/etnologia , Neoplasias Hepáticas/genética , Neoplasias Hepáticas/patologia , Aprendizagem em Labirinto
5.
Braz. j. med. biol. res ; 45(3): 273-283, Mar. 2012. ilus, tab
Artigo em Inglês | LILACS | ID: lil-618048

RESUMO

Chronic atrophic gastritis (CAG) is a very common gastritis and one of the major precursor lesions of gastric cancer, one of the most common cancers worldwide. The molecular mechanism underlying CAG is unclear, but its elucidation is essential for the prevention and early detection of gastric cancer and appropriate intervention. A combination of two-dimensional gel electrophoresis and mass spectrometry was used in the present study to analyze the differentially expressed proteins. Samples from 21 patients (9 females and 12 males; mean age: 61.8 years) were used. We identified 18 differentially expressed proteins in CAG compared with matched normal mucosa. Eight proteins were up-regulated and 10 down-regulated in CAG when compared with the same amounts of proteins in individually matched normal gastric mucosa. Two novel proteins, proteasome activator subunit 1 (PSME1), which was down-regulated in CAG, and ribosomal protein S12 (RPS12), which was up-regulated in CAG, were further investigated. Their expression was validated by Western blot and RT-PCR in 15 CAG samples matched with normal mucosa. The expression level of RPS12 was significantly higher in CAG than in matched normal gastric mucosa (P < 0.05). In contrast, the expression level of PSME1 in CAG was significantly lower than in matched normal gastric mucosa (P < 0.05). This study clearly demonstrated that there are some changes in protein expression between CAG and normal mucosa. In these changes, down-regulation of PSME1 and up-regulation of RPS12 could be involved in the development of CAG. Thus, the differentially expressed proteins might play important roles in CAG as functional molecules.


Assuntos
Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Mucosa Gástrica/química , Gastrite Atrófica/metabolismo , Proteínas Musculares/genética , Proteômica , Complexo de Endopeptidases do Proteassoma/genética , Proteínas Ribossômicas/metabolismo , Western Blotting , Doença Crônica , Regulação para Baixo , Eletroforese em Gel Bidimensional , Mucosa Gástrica/patologia , Gastrite Atrófica/genética , Helicobacter pylori , Espectrometria de Massas , Proteínas Musculares/metabolismo , Complexo de Endopeptidases do Proteassoma/metabolismo , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Proteínas Ribossômicas/genética , Regulação para Cima
6.
Acta physiol. pharmacol. ther. latinoam ; 48(3): 115-23, 1998. tab, graf
Artigo em Inglês | LILACS | ID: lil-216879

RESUMO

Here we demonstrate that T. cruzi antigen molecule SAPA (shed acute phase antigen) with neuraminidase-trans sialidase activity triggers down-regulation of T lymphocyte proliferation by interacting with T lymphocyte muscarinic acetylcholine receptors (mAChR). SAPA attachment to mAChR from Lyt 2.2+ T cells resulted in synthesis of cyclic GMP (cGMP) and secretion of PGE2, an immunoregulator effector substance. These T suppressor cell signals were blunted by atropine and by indomethacin. Cell sorter analysis showed that the interaction of SAPA with purified T cells, affected the ratio of L3T4+/Lyt 2.2+ T cells increasing the percentage of Lyt 2.2+ T cells, effect that was inhibited by the mAChR antagonist, atropine. The interaction between SAPA and mAChR from Lyt 2.2+ T cells may result, therefore, in the down-regulation of the host immune response as consequence of T suppressor/cytotoxic cells activation and PGE2 release as they were observed. These results support the theory of an immunosuppressive state that contribute to the chronic course of Chagas'disease.


Assuntos
Animais , Camundongos , Antígenos de Protozoários/efeitos dos fármacos , Atropina/farmacologia , Inibidores de Ciclo-Oxigenase/farmacologia , Dinoprostona/metabolismo , Regulação para Baixo/efeitos dos fármacos , Indometacina/farmacologia , Antagonistas Muscarínicos/farmacologia , Receptores Muscarínicos/imunologia , Linfócitos T/efeitos dos fármacos , Trypanosoma cruzi/imunologia , Divisão Celular , Doença de Chagas/imunologia , Doença Crônica , Concanavalina A , GMP Cíclico/imunologia , Dinoprostona/imunologia , Citometria de Fluxo , Camundongos Endogâmicos BALB C , Linfócitos T/citologia , Linfócitos T/imunologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA